Celltrion’s Remsima & Samsung’s SB5 about to be launched in US and Europe
Celltrion(CEO Jung-jin Seo) and Samsung Bioepis(CEO Han-seung Ko) got a step closer to pioneering the U.S. and European markets.
According to the industry concerned, a U.S. patent suit on a Celltrion’s Remicade biosimilar, ‘Remsima,’ will be ruled at a local time on the 16th.
If Celltrion wins,...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
